A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Exclusion Criteria

• •Participant has active CMV disease or infection or has received treatment for active CMV disease or infection within 3 months (90 days) prior to transplant
• •Participant has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score ≥ 4
• •Participant has received a prior HCT and has residual Chronic Graft-versus-host Disease (cGVHD)
• •Participant who is scheduled to have a cord blood transplant or a haploidentical transplant
• •Participant has a platelet count of less than 50,000 mm3 within 3 days prior to randomization (platelet transfusions are allowed)
• •Participant has aplastic anemia or multiple myeloma